Terappel : description et exemple(s) d’exploitation

Guideline on the exposure to medicinal products during pregnancy: need for post-authorisation data (EMEA/CHMP/313666/2005). http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/11/WC500011303.pdf Consulté le 17 décembre 2013 (21 pages). Robert-Gnansia, 2002, Méthodes d’évaluation des risques liés aux prises médicamenteuses pendant la grossesse. Avantages et limites de l’épidémiologie, interprétation des résultats, Therapie, 57, 175 The national board of health and welfare, 2003 Chambers, 2004, Organization of teratology information services (OTIS): update and direction. In: NATO Advanced Research Workshop on “Drugs in Pregnancy: Consensus Conference on Teratogen Information Services”, Prague, 16–18 April 2004, Reprod Toxicol, 19, 240 Schaefer, 2005, Post-marketing surveillance system for drugs in pregnancy-15years experience of ENTIS, Reprod Toxicol, 20, 331, 10.1016/j.reprotox.2005.03.012 Eléfant, 1992, Teratogenic agent information centre: fifteen years of counseling and pregnancy follow-up, Teratology, 46, 35, 10.1002/tera.1420460107 Hancock, 2007, The effectiveness of teratology information services (TIS), Reprod Toxicol, 23, 125, 10.1016/j.reprotox.2006.11.005 Jacqz-Aigrain, 2006, Méthodes de surveillance et de gestion des risques des médicaments pour la future mère, l’embryon, le fœtus et le nouveau-né, Therapie, 61, 297, 10.2515/therapie:2006057 Bonnes pratiques de pharmacovigilance. Mise à jour prenant en compte l’arrêté du 10 juin 2011 relatif aux modalités de signalement des effets indésirables par les patients et les associations agréées de patients http://ansm.sante.fr/var/ansm_site/storage/original/application/13df5d1566a748c2f08299233451fe5c.pdf Consulté le 17 décembre 2013 (52 pages Vial, 1989, Tératovigilance. Méthodologie de suivi des appels, Therapie, 44, 453 Garbis, 1990, Experience of two teratology information services in Europe, Teratology, 42, 629, 10.1002/tera.1420420607 Felix, 2004, Postmarketing surveillance for drug safety in pregnancy: the organization of teratology information services project, Birth Defects Res A Clin Mol Teratol, 70, 944, 10.1002/bdra.20090 Lacroix, 2009, Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database, Eur J Clin Pharmacol, 65, 839, 10.1007/s00228-009-0647-2 Källén, 2006, No increased risk of infant hypospadias after maternal use of loratadine in early pregnancy, Int J Med Sci, 3, 106, 10.7150/ijms.3.106 Vial, 2006, Paroxetine and congenital malformations: a prospective comparative study, Drug Saf, 29, 1023, 10.2165/00002018-200629100-00121 Einarson, 2009, Rates of spontaneous and therapeutic abortions following use of antidepressants in pregnancy: results from a large prospective database, Obstet Gynaecol Can, 31, 452, 10.1016/S1701-2163(16)34177-9 Einarson, 2010, Paroxetine use in pregnancy and increased risk of heart defects: evaluating the evidence, Can Fam Physician, 56, 767 Cournot, 2006, Angiotensin-converting enzyme (ACE) inhibitors during first trimester of pregnancy: a French prospective collaborative study, Drug Saf, 29, 927, 10.2165/00002018-200629100-00024 Hoeltzenbein, 2012, Teratogenicity of mycophenolate confirmed in a prospective study of the European network of teratology information services, Am J Med Genet A, 158A, 588, 10.1002/ajmg.a.35223 http://www.audipog.net/ Consulté le 17 décembre 2013. Bernard, 2013, Continuation of pregnancy after first-trimester exposure to mifepristone: an observational prospective study, BJOG, 120, 568, 10.1111/1471-0528.12147 Lewden, 2004, Low dose methotrexate in the first trimester of pregnancy: results of a French collaborative study, J Rheumatol, 31, 2360 Weber-Schoendorfer, 2012, Is there an increased risk for adverse pregnancy outcome after exposure to low-dose methotrexate during early pregnancy? Bruel, 2012, Outcome of pregnancies exposed to oseltamivir, Fund Clin Pharmacol, 26, 43 Bellet, 2013, Pregnancy outcome in women exposed to aripiprazole during the embryonic period: a prospective multicentric cohort, Fund Clin Pharmacol, 27, 43 Vial, 2009, Pregnancy outcome in women exposed to atypical antipsychotics, Drug Saf, 32, 933 Gouraud, 2012, Tramadol use in pregnancy: a prospective, comparative study of exposed infants, Drug Saf, 35, 959 Fujii, 2013, Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study, Neurology, 80, 1565, 10.1212/WNL.0b013e31828f18c1 Einarson, 2012, Rates of major malformations in infants following exposure to duloxetine during pregnancy: a preliminary report, J Clin Psychiatry, 73, 1471, 10.4088/JCP.12l08013 Martínez-Frías, 1999, Problems of using data from teratology information services (TIS) to identify putative teratogens, Teratology, 60, 54, 10.1002/(SICI)1096-9926(199908)60:2<54::AID-TERA3>3.0.CO;2-3 Ornoy, 2000, More on data from teratogen information systems (TIS), Teratology, 61, 327, 10.1002/(SICI)1096-9926(200005)61:5<327::AID-TERA2>3.0.CO;2-H Schaefer, 2008, Using observational cohort data for studying drug effects on pregnancy outcome--methodological considerations, Reprod Toxicol, 26, 36, 10.1016/j.reprotox.2008.05.064